结核分枝杆菌Rv2608抗原的多肽预测及实验验证

Prediction and experimental verification of T cell reactive peptides of mycobacterium tuberculosisantigen Rv2608

【摘要】目的寻找结核分枝杆菌抗原Rv2608的T细胞反应多肽，以用于结核病治疗或辅助治疗。方法采用生物信息学方法预测Rv2608的T细胞表位，筛选表位集中、亲和力较强、理化性质稳定的长链多肽，进行化学合成，应用酶联免疫斑点技术检测多肽刺激活动性结核病患者免疫细胞分泌IFN-γ的能力。结果预测并筛选出Rv2608长链多肽4条，ELISPOT结果表明4条多肽可以激活部分活动性结核病患者的免疫细胞，其中Rv2608p3的免疫激活效率最高。结论软件预测与初步鉴定结果具有一致性，Rv2608p3可用于结核病治疗性疫苗的进一步研究。

[ Abstract] Objective To discover T cell reactive peptides of mycobacterium tuberculosis antigen Rv2608 for treatment or adjuvant treatment for tuberculosis. Methods The T cell epitopes of Rv2608 were predicted by bioinformaties. The long-chain peptides were screened with strong affinity with HLA-A0201, HLA-AI I01, and HLA-A2402. The physical and chemical characters of the peptides were predicted. The stable and hydrophilic peptides for chemical synthesis were selected. The T cell reactivity of the peptides in patients with active tuberculosis was detected by ELISPOT. The results were compared with the clinical di- agnosis kits TSPOT. TB. Results Four peptides of Rv2608 were predicted and screened, and they could be active T cells of patients with active TB. Rv2608p3 was the most efficient to prime the T cell response. Conclusions Software prediction was consistent with the result of ELISPOT. Rv2608p3 might be the can- didate for therapeutic vaccine for tuberculosis.